抗表皮生長因子受體抗體(Anti-EGFR)檢測試劑盒(酶聯(lián)免疫吸附試驗法)
ELISA Kit for Anti-Epidermal Growth Factor Receptor Antibody (Anti-EGFR)
ErbB-1; ErbB1; ER1; ERB-B1; MENA; HER1; Erythroblastic Leukemia Viral(v-Erb-B)oncogene Homolog,Avian; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1
- 編號AEA757Hu
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 實驗方法間接法
- 反應(yīng)時長2h, 30min
- 檢測范圍3.12-200ng/mL
- 靈敏度最小可檢測劑量小于等于1.17ng/mL.
- 樣本類型serum, plasma and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價格 ¥ 3570 ¥ 5100 ¥ 22950 ¥ 43350 ¥ 357000
- 欲了解實際交易價格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實驗結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測抗表皮生長因子受體抗體(Anti-EGFR)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的抗表皮生長因子受體抗體(Anti-EGFR)（加標(biāo)樣品），重復(fù)測定并計算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 81-97 | 85 |
| EDTA plasma(n=5) | 86-96 | 91 |
| heparin plasma(n=5) | 82-94 | 91 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次，分別計算不同濃度樣本的平均值及SD值。
批間差：選取3個不同批次的試劑盒分別對低、中、高值定值樣本進(jìn)行定量測定，每個樣本使用同一試劑盒重復(fù)測定8次，分別計算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的抗表皮生長因子受體抗體(Anti-EGFR)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中抗表皮生長因子受體抗體(Anti-EGFR)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 79-98% | 90-103% | 82-101% | 96-103% |
| EDTA plasma(n=5) | 94-105% | 97-105% | 93-101% | 78-96% |
| heparin plasma(n=5) | 78-97% | 88-95% | 93-105% | 91-101% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實驗室的環(huán)境條件需盡量保持一致，尤其是實驗室內(nèi)溫度、濕度及溫育條件。其次由同一實驗員來進(jìn)行操作可減少人為誤差。
實驗流程
1. 實驗前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時；
3. 吸棄，加檢測溶液A100μL，37°C孵育1小時；
4. 洗板5次；
5. 加TMB底物90µL，37°C孵育10-20分鐘；
6. 加終止液50µL，立即450nm讀數(shù)。
實驗原理
將抗原包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的抗表皮生長因子受體抗體(Anti-EGFR)與連接于固相載體上的抗原結(jié)合，然后加入HRP標(biāo)記的二抗，徹底洗滌后加入TMB底物顯色。TMB在過氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的抗表皮生長因子受體抗體(Anti-EGFR)呈正相關(guān)。用酶標(biāo)儀在450nm波長下測定吸光度(O.D.值)，計算樣品濃度。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| APA757Hu01 | 表皮生長因子受體(EGFR)活性蛋白 | Cell?culture;?Activity?Assays. |
| APA757Hu02 | 表皮生長因子受體(EGFR)活性蛋白 | Cell?culture;?Activity?Assays. |
| APA757Hu62 | 表皮生長因子受體(EGFR)活性蛋白 | Cell?culture;?Activity?Assays. |
| RPA757Hu01 | 表皮生長因子受體(EGFR)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APA757Hu61 | 表皮生長因子受體(EGFR)活性蛋白 | Cell?culture;?Activity?Assays. |
| EPA757Hu62 | 表皮生長因子受體(EGFR)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA757Hu02 | 表皮生長因子受體(EGFR)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| EPA757Hu61 | 表皮生長因子受體(EGFR)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA757Hu06 | 表皮生長因子受體(EGFR)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA757Hu02 | 表皮生長因子受體(EGFR)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA757Hu01 | 表皮生長因子受體(EGFR)多克隆抗體 | WB; IHC; ICC; IP. |
| FAA757Hu51 | 抗表皮生長因子受體(EGFR)多克隆抗體(別藻藍(lán)蛋白標(biāo)記) | FCM |
| MAA757Hu27 | 表皮生長因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA757Hu29 | 表皮生長因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
| RAA757Hu21 | 表皮生長因子受體(EGFR)重組抗體 | WB; IF; ICC; IHC; IP; FCM. |
| MAA757Hu21 | 表皮生長因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA757Hu23 | 表皮生長因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA757Hu24 | 表皮生長因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA757Hu25 | 表皮生長因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA757Hu22 | 表皮生長因子受體(EGFR)單克隆抗體 | WB; IHC |
| SEA757Hu | 表皮生長因子受體(EGFR)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| HEA757Hu | 表皮生長因子受體(EGFR)檢測試劑盒(酶聯(lián)免疫吸附試驗法,高敏型) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| AEA757Hu | 抗表皮生長因子受體抗體(Anti-EGFR)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antibody Detection. |
| LMA757Hu | 表皮生長因子受體(EGFR)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Thoracic Cancer | Nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer [Wiley: source] |
| J Cent Nerv Syst Dis.? | Increased Epidermal Growth Factor Receptor (EGFR) Associated with Hepatocyte Growth Factor (HGF) and Symptom Severity in Children with Autism … [Pubmed:25249767] |
| Mol Cancer Ther | GC1118, an anti-EGFR antibody with a distinct binding epitope and superior inhibitory activity against high-affinity EGFR ligands [PubMed: 26586721] |
| Cell Death Dis.? | LINC01225 promotes occurrence and metastasis of hepatocellular carcinoma in an epidermal growth factor receptor-dependent pathway [Pubmed:26938303] |
| analytica chimica acta | Microfluidic immunosensor based on mesoporous silica platform and CMK-3/poly-acrylamide-co-methacrylate of dihydrolipoic acid modified gold electrode for cancer biomarker detection. [pubmed:28335979] |
| Talanta | EGFR detection in extracellular vesicles of breast cancer patients through immunosensor based on silica-chitosan nanoplatform [Doi: 10.1016/j.talanta.2018.10.016] |
| Bioorganic Chemistry | Design, synthesis, molecular docking and biological activity evaluation of some novel indole derivatives as potent anticancer active agents and apoptosis inducers [Pubmed: 30665034] |
| Journal of?enzyme?inhibition and medicinal chemistry | Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile [Pubmed: 30919701] |
| Bioorganic Chemistry | Design and synthesis of new benzoxazole/benzothiazole-phthalimide hybrids as antitumor-apoptotic agents [] |
| Bioorganic Chemistry | Synthesis and anticancer activity of bis-benzo [d][1, 3] dioxol-5-yl thiourea derivatives with molecular docking study [Pubmed: 31288134] |
| Oxidative Medicine and Cellular Longevity | Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters?… [Pubmed: 31737175] |
| Neoplasia | Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine [Pubmed: 33212364] |
| Association between Serum Epidermal Growth Factor Receptor and Cyclooxygenase-2 Levels in Patients with Non-small Cell Carcinoma of Lung [] | |
| Synthesis, EGFR-TK inhibition and anticancer activity of new quinoxaline derivatives [] | |
| IMMUNOLOGIC RESEARCH | Humoral immune response to epidermal growth factor receptor in lung cancer [33495907] |
| European Journal of Medicinal Chemistry | Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure¨Cactivity relationship and biological activity as potential antitumor and anticonvulsant agents [33545637] |
| Journal of Molecular Structure | Design, synthesis, antiproliferative evaluation, and molecular docking study of new quinoxaline derivatives as apoptotic inducers and EGFR inhibitors [] |
| ACS Appl Mater Interfaces | Emitter–Quencher Pair of Single Atomic Co Sites and Monolayer Titanium Carbide MXenes for Luminol Chemiluminescent Reactions [34914377] |
| Bioorganic Chemistry | Discovery of new pyrimido [5, 4-c] quinolines as potential antiproliferative agents with multitarget actions: Rapid synthesis, docking, and ADME studies [Pubmed:35219045] |
